Northwestern Medicine investigators have discovered previously unknown metabolic changes that may contribute to the development of estrogen receptor–negative (ERneg) breast cancer, according to recent ...

Published in the journal RSC Medicinal Chemistry, new research targets two critical enzymes involved in the production of the hormone oestrogen —aromatase and steroid sulfatase—at the same time.

According to the National Cancer Institute, roughly 15% of breast cancer cases are hormone-receptor negative, in which breast cancer cells do not contain hormone (estrogen or progesterone) receptors.